免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据,仅供一般参考,不构成医疗建议、诊断、治疗建议或投资建议。

FDA 510(k)

0.9%氯化钠注射剂,USP,BD PosiFlush® SP注射器

K号: K250884 · 2025-12-02

决定日期2025-12-02
产品代码NGT
咨询委员会医疗设备监管文本翻译如下: HO 请注意,由于您没有提供具体的医疗设备监管文本内容,以上仅为示例。请提供具体的文本内容以便进行准确的翻译。
决定实质等同

器械摘要

0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe is the device name listed in this FDA 510(k) record. The listed applicant is Becton, Dickinson and Company. It received FDA 510(k) clearance on 2025-12-02 under 510(k) number K250884. The device is classified under product code NGT. It was reviewed by the HO advisory panel. FDA Decision: Substantially Equivalent.

常见问题

What is the 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe?

0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe is a medical device that received FDA 510(k) clearance on 2025-12-02. The listed applicant is Becton, Dickinson and Company. The 510(k) number is K250884.

When did 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe receive FDA 510(k) clearance?

0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe received FDA 510(k) clearance on 2025-12-02, under 510(k) number K250884.

Who is the listed applicant for 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe?

The FDA 510(k) record lists Becton, Dickinson and Company as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe?

The FDA product code for 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe is NGT.

相关临床试验

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

列明Becton, Dickinson and Company为申报人的其他记录

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

查看所有 102 个设备 →

相关器械(代码:NGT)

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

官方来源

在 FDA 数据库中查看 →

数据来源于FDA开放API。如需最新且权威的信息,请务必参考官方记录。

↑